BioCurie
June 24, 2026
5B
Type: Start-Up Stadium Session
Focus Area:
Cell and Gene Therapy and Genome Editing
BioCurie is a TechBio startup pioneering mechanistic artificial intelligence (mAI) to transform the development and manufacturing of cell, gene, and RNA therapies (CGT). Our patented BioCurie™ mAI software platform enables biopharmaceutical companies and manufacturers to rapidly develop and produce CGTs that are safe, effective, and commercially scalable. BioCurie has strong momentum, including a a $9M contract with ARPA-H to develop a scalable AI-driven digital platform for gene therapy production, a contract with a Top 25 pharma customer converting from pilot to SaaS in 2026, signed and pending contracts valued at $2.2M with global biopharma companies. BioCurie’s foundational patent has entered the National Stage with a favorable USPTO report, and we have received positive feedback from the FDA. BioCurie has been invited to educate HHS on AI-driven decision-making for CGT production and has won multiple global innovation awards, including the Cure Xchange Health AI for Good Award (2024) and the King Faisal and Davos of Healthcare Innovation AI Challenge (2025).
Company HQ City:
Wilmington
Company HQ State:
Delaware
Company HQ Country:
United States
Year Founded:
2021
CEO
Irene Rombel
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}